CYP3A4

E Vicipaedia
Jump to navigation Jump to search
Esculaap4.svg
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.


Cytochroma P450 CYP3A4.

Cytochroma P450 CYP3A4 (-atis, n.) (Numerus EC: 1.14.13.97) est haemoproteinum et pars gregis Cytochroma P450 ideo in metabolismo xenobioticorum interest. CYP3A4 est maximum exprimatum omnium cytochromatum iocineris humani[1].

Locus[recensere | fontem recensere]

Pharmaca ad CYP3A4 relata[recensere | fontem recensere]

Multa chemotherapeutica, analgetica, cardiaca, psychopharmaca substratum cytochromatis 3A4 sunt. Inhibitores ut proteasis inhibitores (SCDI!) effectus substratorum augere possunt.

Pharmaca relata ad CYP3A4[2][3].
Substrati Inhibitores[4] Inductores[5]
  • Anticonvulsiva
    • Carbamazepinum (forte, quoque P-gp)
    • Phenytoinum (forte)
    • Fosphenytoinum (forte)
    • Oxcarbazepinum (forte)
    • Topiramatum
    • Phenobarbitalum (forte)
    • Primidonum (forte)
  • Antidepressiva
    • Hypericum perforatum (forte, quoque P-gp)
  • Antihypertensiva
    • Bosentanum (forte, endothelini receptoris inhibitor)
  • Substantiae antiretrovirales
    • Efavirenzum (forte)
    • Etravirinum (forte)
    • Nevirapinum (forte)
  • Substantiae antineoplasticae
    • Enzalutamidum
    • Mitotanum (forte)
  • Antibiotica
    • Rifabutinum (forte)
    • Rifapentinum (forte)
    • Nafcillinum (forte)
    • Rifampicinum (forte)
  • Hormonta
    • Triiodthyroninum (T3)
  • Modafinilum
  • Quercetinum
  • Capsaicinum

Notae[recensere | fontem recensere]

  1. Liddle, C; Goodwin, BJ; George, J; Tapner, M; Farrell GC (July 2003). "Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes". J Clin Endocrinol Metab 83 (7): 2411-6 
  2. Cozza KL, Armstrong SC (2001). The Cytochrome P450 System. Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing
  3. Preskorn SH (1996). Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed.: Professional Communications, Inc.
  4. Inhibitor cum subtratorum effectibus fortioribus
  5. Inductor cum subtratorum effectibus minoribus
  6. Yuji Horikiri; Takehiko Suzuki; Masakazu Mizobe (March 1998). "Pharmacokinetics and metabolism of bisoprolol enantiomers in humans". Journal of Pharmaceutical Sciences 87 (3): 289–294 
  7. Gandhi S, Fleet JL, Bailey DG, McArthur 4, Wald R, Rehman F2, Garg AX (dec 2013). "Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury". JAMA 18 (23): 2544-53 
  8. Kronbach, T; Fischer, V; Meyer UA (June 1988). "Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.". Clin Pharmacol Ther 43 (6): 630-5 
  9. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED (1995). "Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism". Drug Metab Dispos 23 (4): 490-6 
  10. 10.0 10.1 Apixabanum et Rivaroxabanum / P-gp et inductores fortes CYP3A4 (Anglice)
  11. Apixabani interactionum effectus (Anglice)

Nexus externi[recensere | fontem recensere]